VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

18 A EGIS C APITAL C ORP. Management Shawn K. Singh is Chief Executive Officer and Director at VistaGen Therapeutics, Inc. and Chief Operating Officer & General Counsel at Cato Holding Co. Mr. Singh is also on the board of Armour Therapeutics, Inc. and Member of The State Bar of California. Previously, he was Chief Executive Officer at VistaGen, Inc., Director at Echo Therapeutics, Inc. Chairman of Sontra Medical Corp. Chairman of Durham Pharmaceuticals and Chairman of Echo Therapeutics, Inc. (all subsidiaries of Echo Therapeutics, Inc.), Corporate Finance Associate at Morrison & Foerster LLP, Chief Business Officer for SciClone Pharmaceuticals, Inc., Managing Director at Start-up Law, Principal at Celerity Fund, Inc., Chief Business Officer & General Counsel at Cato Research LLC and Managing Principal at Cato BioVentures (a subsidiary of Cato Research LLC), Chief Executive Officer & Director at Excaliber Enterprises Ltd., Chief Executive Officer of VistaGen Therapeutics, Inc. and President at Artemis Neuroscience, Inc. Mr. Singh received an undergraduate degree from the University of California, Berkeley and a graduate degree from The University of Maryland Francis King Carey School of Law. H. Ralph Snodgrass is Founder, President, Director & Chief Scientific Officer at VistaGen Therapeutics. Dr. Snodgrass was previously Chief Executive Officer for VistaGen, Inc., Executive Director & Chief Scientific Officer at Progenitor, Inc., Professor at Lineberger Comprehensive Cancer Center, President, Director & Chief Scientific Officer at Excaliber Enterprises Ltd., President & Chief Scientific Officer at VistaGen Therapeutics, Inc., Member of Basel Institute for Immunology and Professor at UNC School of Medicine. Dr. Snodgrass received a doctorate from the University of Pennsylvania. Jerrold D. Dotson is Chief Financial Officer, Secretary & VP at VistaGen Therapeutics, Inc. Previously, Mr. Dotson was Secretary, Vice President-Finance & Administration at Calypte Biomedical Corp., Chief Financial Officer of California & Hawaiian Sugar Co. and Controller at Discovery Foods LLC. Mr. Dotson received an undergraduate degree from Abilene Christian University. Mark A. Smith is Chief Medical Officer of VistaGen Therapeutics, Inc. In the past, Dr. Smith held the position of Executive Director-Clinical Development at AstraZeneca Plc and Senior Director- Experimental Medicine at Shire Plc. He received an undergraduate degree and a graduate degree from Yale University and a doctorate from the University of California San Diego. Mark A. McPartland is Vice President-Corporate Development for VistaGen Therapeutics, Inc. He was previously Vice President & Partner at Alliance Advisors LLC, Regional Vice President at Hayden Communications, Inc., Senior Vice President-Southeast US at MZ Group and VP- Corporate Development & Communications at Stellar Biotechnologies, Inc. Mark A. McPartland received an undergraduate degree from Coastal Carolina University. VistaGen Therapeutics, Inc. October 8, 2020